Latest filing published 03 Jul 2019 for Fusion Antibodies plc, €5,628.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +32.1%Entry £0.66 · Close at T+365 £0.86
- +51.8%Entry £0.85 · Close at T+365 £1.29
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Paul Kerr: trading record in brief
All filings by Paul Kerr on record concern Fusion Antibodies plc. Over a trading history stretching from 29 April 2019 to 2 July 2019, the count stands at 2 filings.
No open-market sale appears; the market trades are 2 purchases worth €6,776. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
On 3 July 2019 came the latest disclosure, an open-market purchase for €5,628 in Fusion Antibodies plc. This summary is built from RNS (LSE) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Paul Kerr
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,920 shares@ £0.72983.1% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20190703160914_14135577_20200326185125204_34467-0Canonical exit: 30 Sept 2019 (T+90)
- 1,290 shares@ £0.77100.0% of flowLondon Stock Exchange, XLONISIN GB00BDQZGK16FCA-NSM:LSE20190429144627_14055876_20200326185040667_1701Canonical exit: 28 Jul 2019 (T+90)
2 of 2 declarations